Skip to main content

$0.042 -0.001 (-2.33%)

High

$0.04

Low

$0.04

Trades

17

Turnover

$24,861

Volume

582,113
30 June 2023 at 3:56pm
Register to track ACR and receive email alerts.

Acrux Receives FDA Approval - Generic Efinaconazole Solution

StockBot

416,823 posts

ACR released this announcement to the ASX on 22 June 2021, 9:40. The announcement is marked as price sensitive, and is 2 page(s) in length and 193.2kb in size.

You can view all announcements from ACR and see how they appear on a price chart on the announcements page.

At the date of this announcement, ACR was 0.004% short sold according to ASIC data. It was ranked the 605th most shorted stock on the ASX. It is now ranked as the 374th most shorted stock on the ASX with 0.210% of total shares short sold as of the latest reported data (06 December 2024).

Other Recent Announcements from ACR
Appendix 3Y Brooke 16 June 2023, 9:27
Application for quotation of securities - ACR 16 June 2023, 9:25
4th FDA ANDA approval received - Dapsone Gel, 5% 7 June 2023, 10:35
Acrux Receives FDA Approval - Generic Efinaconazole Solution 22 June 2021, 9:40
Notification of cessation of securities - ACR 21 June 2021, 15:52
Change in Company Secretary 21 June 2021, 8:55
Change of Director's Interest Notice - Ross Dobinson 17 June 2021, 12:34
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track ACR and receive email alerts.